Forget a Cash ISA! I’d aim to make a passive income with these 2 FTSE 100 dividend stocks

I think these two FTSE 100 (INDEXFTSE:UKX) income shares appear to offer favourable prospects when compared to a Cash ISA.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since the best returns available on a Cash ISA are currently around 1.5%, buying FTSE 100 dividend shares could prove to be a shrewd move.

In many cases, it is possible to double, or even treble, your passive income when compared to Cash ISA rates.

With interest rates set to remain at their current level, or even fall, over the next few years, now could be a good time to buy these two large-cap income shares. They appear to have sound strategies that could produce capital growth alongside their income returns.

AstraZeneca

With a 3.1% dividend yield, AstraZeneca (LSE: AZN) may not be among the highest-yielding shares in the FTSE 100. However, the pharmaceutical company’s dividend growth prospects could make it a sound income opportunity for the long run.

Its recent updates have shown that its pipeline has improved dramatically in recent years after an ambitious investment programme. This could position the company for growth in a world where demographic challenges may catalyse demand for a wide range of healthcare products and services.

AstraZeneca’s defensive business model may prove to be attractive to many investors during what is a period of significant economic and political risk.

Furthermore, with its dividend expected to be covered 1.3 times by net profit in the current year, there seems to be scope for its shareholder payouts to rise at a brisk pace. This could lead to a strong and dependable passive income stream for its investors that catalyses its share price over the long run.

British Land

Real estate investment trust (REIT) British Land (LSE: BLND) is a very different investment proposition than AstraZeneca. The property company is facing a period of disruption across much of its asset base, with demand for retail units expected to come under pressure over the medium term as online shopping becomes increasingly popular.

This could cause rents to decline, which may put the company’s dividend growth rate under a degree of pressure. However, with British Land shifting its focus away from retail and towards faster-growing areas such as flexible office space, it seems to have a sound strategy that could lead to improving financial performance in the long run.

Furthermore, investors appear to have factored in the risks facing the business. It trades on a price-to-book (P/B) ratio of just 0.6, while its dividend yield of 5.4% is among the highest yields currently available in the FTSE 100.

Certainly, British Land may prove to be a relatively risky stock to own in the short run, as it aims to transition towards assets that have greater growth potential. For long-term income investors, now could be the right time to buy a slice of the business based on its high income return and wide margin of safety. It could offer high total returns in the coming years.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca and British Land Co. The Motley Fool UK has recommended AstraZeneca and British Land Co. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »